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Abstract: Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized
as a distinct entity, due to its unique biological and clinical features. We summarize here the
results of published studies investigating the clinical application of minimal/measurable residual
disease (MRD) in patients with NPM1-mutated AML, receiving either intensive chemotherapy
or hematopoietic stem cell transplantation. Several clinical trials have so far demonstrated a
significant independent prognostic impact of molecular MRD monitoring in NPM1-mutated AML
and, accordingly, the Consensus Document from the European Leukemia Net MRD Working
Party has recently recommended that NPM1-mutated AML patients have MRD assessment at
informative clinical timepoints during treatment and follow-up. However, several controversies
remain, mainly with regard to the most clinically significant timepoints and the MRD thresholds
to be considered, but also with respect to the optimal source to be analyzed, namely bone marrow
or peripheral blood samples, and the correlation of MRD with other known prognostic indicators.
Moreover, we discuss potential advantages, as well as drawbacks, of newer molecular technologies
such as digital droplet PCR and next-generation sequencing in comparison to conventional RQ-PCR
to quantify NPM1-mutated MRD. In conclusion, further prospective clinical trials are warranted to
standardize MRD monitoring strategies and to optimize MRD-guided therapeutic interventions in
NPM1-mutated AML patients.
Keywords: NPM1-mutated acute myeloid leukemia; molecular minimal/measurable residual disease
monitoring; prognostic thresholds and timepoints; intensive chemotherapy; allogeneic hematopoietic
stem cell transplantation; clinical outcome
1. Introduction
The results of cytogenetic and molecular examinations at diagnosis of non-promyelocytic acute
myeloid leukemia (AML), combined with the achievement of morphologic complete remission (CR)
after remission induction chemotherapy, have significant prognostic impact on clinical outcome and
usually serve to guide post-remission therapeutic strategies in younger adult patients [1–3]. However,
the morphologic assessment of bone marrow (BM) blast percentage by light microscopy is significantly
hampered by limited sensitivity and inter-observer variability, so that it is generally recognized that,
when 5% myeloblasts is considered to be the cut-off to define morphologic CR, about 1010 leukemic
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cells may still persist in the patient [3,4]. The risk stratification in AML patients actually remains
inadequate, and there is growing interest in the use of more sensitive laboratory tools, such as
multiparametric flow cytometry (MFC) or molecular techniques, to detect low levels of residual
disease in either BM or peripheral blood (PB) at different treatment timepoints [1]. The evaluation of
minimal residual disease, also referred to as measurable residual disease (MRD), is considered useful to
more precisely define AML response to intensive chemotherapy, thereby refining risk stratification [1].
Some studies have demonstrated that MRD persistence in a condition of morphologic CR confers high
relapse risk and adverse prognosis, comparable to the one associated with persisting leukemic cells
at microscopic examinations [4–6]. Interestingly, the recently revised European Leukemia Net (ELN)
recommendations for AML management have introduced the category CR without MRD (CRMRD−) [7].
Moreover, long-term MRD monitoring in patients in CR may serve to early detect leukemia relapse [1].
MRD assessment captures the diversities of the underlying cytogenetic/genetic AML characteristics
and also recapitulates patients’ heterogeneity regarding chemotherapy bioavailability, metabolism
and resistance, thus resulting in a unique in vivo tool to evaluate chemosensitivity of leukemic
cells [4,8,9]. Moreover, even within homogeneous genetic subgroups, the long-term outcome of AML
patients depends on the clearance of the molecular lesion, as clearly demonstrated in other myeloid
neoplasms, namely chronic myeloid leukemia and acute promyelocytic leukemia [1,4]. Beyond
MFC, several molecular techniques are currently available for MRD determination in AML patients,
including real-time quantitative polymerase chain reaction (RQ-PCR), which is highly sensitive, reliable,
rapid and reproducible between different laboratories, as well as newer but less standardized tools such
as next-generation sequencing (NGS) and digital droplet PCR (ddPCR) [2,4]. RQ-PCR allows MRD
detection in patients with documentation of chimeric fusion genes generated by balanced chromosomal
rearrangements, especially in cases of acute promyelocytic leukemia and core-binding factor (CBF)
leukemias, but also in AML cases with other genetic alterations, such as insertions/duplications (e.g.,
NPM1, FLT3-ITD, MLL-PTD), point mutations (CEBPA, IDH1/2, KIT, RAS, RUNX1, TP53) or gene
overexpression (WT1, EVI1, ERG) [1,2,4]. While MFC, despite its limitations, could enable MRD
assessment in the vast majority of AML patients, a major drawback of RQ-PCR is its applicability only
to those cases, accounting for approximately 50–60% of younger AML patients, who bear at least one
molecular lesion, specific and stable over the treatment course, which could reliably be monitored
using this molecular technique [2,4,10].
2. NPM1 Mutations in AML: Biological and Clinical Features
Nucleophosmin (NPM1) gene encodes for a protein which physiologically shuttles between
nucleus and cytoplasm, acting as a molecular chaperone to establish multiple protein-protein
interactions [11]. NPM1 protein is normally involved in critical cell functions, such as control of
ribosome formation and export, stabilization of the oncosuppressor p14Arf protein in the nucleolus,
and regulation of centrosome duplication [12–14]. NPM1 gene mutations, occurring in approximately
30% of adult AML cases, and in 50–60% of AML cases with normal karyotype, represent one of the
most frequent molecular lesions observed in AML [14,15]. Since the discovery of NPM1 mutations
in 2005 by Falini et al. [16], more than 55 different mutations, mainly occurring in the exon 12 of the
gene, have been described, but three mutation types (A, B and D) account for 95% of all cases [8,14,17].
NPM1 gene mutations result in structural changes of the C-terminus of NPM1 protein, with subsequent
aberrant cytoplasmic delocalization, leading to a unique immunohistochemical pattern detectable
on BM trephine biopsy [16,18]. This cytoplasmic accumulation of NPM1-mutated protein causes
perturbations of multiple cellular pathways through a combination of loss of functions and gain of
functions, critical for leukemogenesis [12–14,17]. Notably, it was recently reported that NPM1-mutated
protein dislocated PU.1 into cytoplasm with it, whereas CEBPA and RUNX1, the master transcription
factors that collaborate with PU.1 to activate granulo-monocytic lineage-fates, remained in the nucleus.
However, without nuclear PU.1, their coregulator interactions were toggled from coactivators to
corepressors, thus repressing >500 granulocyte and monocyte terminal differentiation genes [19].
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As expected for founder genetic lesions, NPM1 mutations are specific, being almost
exclusively restricted to AML, usually de novo, and generally expressed in the whole leukemic
population [13,14,20]. Notably, NPM1-mutated AML, showing distinctive genetic, pathologic,
immunophenotypic and clinical features, has now been recognized as a full distinct entity among
AML with recurrent genetic abnormalities in the 2016 revision of World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia [21]. While the infrequent presence of
coexisting chromosomal abnormalities, observed in only 15% of patients, does not appear to modify
the prognostic effects of NPM1 mutations [7,22,23], prognosis may be significantly influenced by
accompanying molecular lesions, mainly FLT3 and DNMT3A gene mutations, documented in about
40% and 50% of NPM1-mutated AML cases, respectively [7,15,17]. In detail, the better risk outcomes
observed in NPM1-mutated AML patients were generally considered limited to cases without
concurrent FLT3-ITD mutations [17,24]. Furthermore, the deleterious prognostic effects of FLT3-ITD
have previously been found to be most clinically relevant when co-occurring with NPM1 and DNMT3A
mutations, as opposed with either mutation alone [25]. However, recent studies have suggested that
patients with NPM1 mutation and FLT3-ITD with a low (<0.5) allelic ratio have a similar favorable
outcome as patients with NPM1-mutated AML without FLT3-ITD [26–29]. Thus, both of these latter
groups are currently considered favorable according to the 2017 ELN risk stratification, in contrast
to NPM1-mutated AML associated with FLT3-ITD with high allelic ratio, which is characterized by
higher relapse rate and poorer overall survival (OS) [7].
3. ELN Recommendations for MRD Assessment
Based upon the above-mentioned biological and clinical characteristics, especially their
homogeneous mutation pattern in AML patients, NPM1 mutations may be considered an ideal
leukemia-specific target for MRD detection [2]. Since the first application by Gorello et al. of
sensitive and specific RQ-PCR assays as a reliable system to quantitatively assess NPM1-mutated
gene copies [30], several studies have investigated the clinical implications of MRD monitoring in
NPM1-mutated AML undergoing intensive therapeutic approaches (Table 1) [30–73].
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Table 1. MRD monitoring in NPM1-mutated AML series: review of the literature.
Reference/Type of
Study
Number of Patients/Median
Age (Years, Range)
Number of Samples
(PB/BM)
Number of Samples per
Patient (Median, Range)
Molecular
Method/Material NPM1 Mutation Type
Sensitivity of the
Assay
Gorello et al.,
2006 [30]/retrospective 20/NA
NA (PB and/or BM
samples at diagnosis
and/or at different
timepoints)
NA (13 patients analyzed at
diagnosis and
post-induction). MRD
kinetics during follow-up of
3 representative patients
is reported
RQ-PCR/cDNA (5 cases),
DNA (15 cases)
A, B (cDNA); A, B, D, E,
G, H (DNA) 10
−3–10−6
Chou et al.,
2007 [31]/retrospective 38/47 (17–87) 194 BM 5 RQ-PCR/DNA 7 different mutations 10
−5
Papadaki et al.,
2008 [32]/retrospective 51/58 (22–78) 154 (18 PB/136 BM)
NA (26 patients analyzed at
diagnosis and at least at
2 timepoints during therapy;
27 patients analyzed at
diagnosis and after
induction therapy)
RQ-PCR/cDNA A 10−5
Barragan et al.,
2008 [33]/- 24/17 cases (71%) <60 yeas 97 (5 PB/92 BM) NA RQ-PCR/cDNA A 10
−5
Bacher et al.,
2009 [34]/retrospective 13/47 (20–66) 139 (PB/BM) 7 (2–25) RQ-PCR/DNA A, B 10
−4–10−6
Schnittger et al.,
2009 [35]/retrospective 252/59 (20–79)
1227 (28 PB at
diagnosis/1199 BM) 4 (2–16) RQ-PCR/cDNA 17 different mutations 10
−4–10−6
Stahl et al.,
2010 [36]/retrospective 25/53 (21–73) 76 (38 PB/38 BM) 1–2 RQ-PCR/DNA A 10
−4–10−6
Dvorakova et al.,
2010 [37]/retrospective 25/51 (43–75) 1026 (339 PB/687 BM) 28 (11–68) RQ-PCR/DNA 9 different mutations 10
−4–10−6
Ommen et al.,
2010 [38]/retrospective 180 (54 in HR)/NA
193 CCR and 70 relapse
samples NA RQ-PCR/cDNA NA 10
−4–10−6
Kristensen et al.,
2011 [39]/retrospective 20/61 (41–76) 204 NA RQ-PCR/DNA A 2.4 × 10
−5
Kronke et al.,
2011 [40]/retrospective 245/49 (19–61) 1682 (410 PB/1272 BM) NA RQ-PCR/cDNA 6 different mutations 10
−5–10−6
Thol et al.,
2012 [41]/retrospective 10/NA (adult patients) 45 NA
NGS, RQ-PCR/DNA,
cDNA
3 different mutations
(8 cases A, 1 case D,
1 case atypical)
10−4
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Table 1. Cont.
Reference/Type of
Study
Number of Patients/Median
Age (Years, Range)
Number of Samples
(PB/BM)
Number of Samples per
Patient (Median, Range)
Molecular
Method/Material NPM1 Mutation Type
Sensitivity of the
Assay
Abdelhamid et al.,
2012 [42]/retrospective 20/55 (27–69)
116 (20 at diagnosis,
96 follow-up samples,
namely 55 PB and
41 BM)
4.5 (2–11) RQ-PCR/DNA 3 different mutations(A, B, insCACG) 10
−4–10−5
Schiller et al.,
2012 [43]/retrospective
30 (among 54 FLT3-ITD+
patients)/62 NA NA RQ-PCR/cDNA NA 10
−4–10−6
Shayegi et al.,
2013 [44]/retrospective 155/51 (20–79) 1750 (817 PB/933 BM) NA RQ-PCR/DNA A, B, D 10
−5
Jeziskova et al.,
2013 [45]/retrospective
6 (among 8 patients with
IDH2 mutations)/57 (53–72) 60 (17 PB/43 BM) 3–14 RQ-PCR/DNA A, B 10
−4–10−6
Salipante et al.,
2014 [46]/retrospective 6/NA 22 BM 2–6 NGS/DNA
No need for
mutation-specific probes 10
−5
Hubmann et al.,
2014 [47]/retrospective 158/57 (18–80) 588 BM NA RQ-PCR/cDNA A, B, D 10
−6
Bacher et al.,
2014 [48]/retrospective 99/NA 498 4 (1–28) digital PCR/cDNA 37 different mutations 10
−4–10−5
Lambert et al.,
2014 [49]/prospective
77 patients with NPM1
mutation/61 (57–65) 250 (125 PB/125 BM) NA RQ-PCR/cDNA A, B, D 10
−5
Debarri et al.,
2015 [50]/retrospective 31/60 (23–70) 94 NA
RQ-PCR for NPM1; NGS
for IDH1/2 and
DNMT3A/cDNA
A, B, D 10−5
Pettersson et al.,
2016 [51]/- 19/64 (28–78) 63 (2 PB/61 BM) 1–9 RQ-PCR/DNA A 10
−5
Karas et al.,
2016 [52]/retrospective 60/54 (30–66) 60 BM 1 (pre-HSCT) RQ-PCR/cDNA A, B, D NA
Alizad Ghandforoush
et al.,
2016 [53]/retrospective
11/42 (28–63) 71 (PB/BM) NA RQ-PCR/DNA A 10−5
Ivey et al.,
2016 [54]/prospective
346 in preliminary
development phase, 91 in
validation cohort/50 (6–68)
2569 in first phase
(1667 PB/902 BM) 6 RQ-PCR/cDNA 27 different mutations 10
−5
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Table 1. Cont.
Reference/Type of
Study
Number of Patients/Median
Age (Years, Range)
Number of Samples
(PB/BM)
Number of Samples per
Patient (Median, Range)
Molecular
Method/Material NPM1 Mutation Type
Sensitivity of the
Assay
Kayser et al.,
2016 [55]/retrospective 67/55 (21–70)
406 (BM) at different
timepoints
pre-transplant MRD was
available for 39/51 (76.4%)
patients in CR at HSCT
(22 cases, 56% MRD-positive)
RQ-PCR/cDNA A, B, D 10−5–10−6
Malmberg et al.,
2017 [56]/retrospective
17 (3 NPM1-mutated
patients)/39 (2–71) NA NA RQ-PCR, NGS/DNA A 10
−5
Balsat et al.,
2017 [57]/retrospective 152/49 (21–61)
304 (PB/BM) at
diagnosis and 270
post-induction
(135 PB/135 BM)
samples obtained at
diagnosis and after
induction CHT
RQ-PCR/cDNA A, B, D 10−5
Schieppati et al.,
2017 [58]/- 68/56 (27–74) NA
4 PB/BM samples (at
diagnosis, TP1 at CR, TP2
post-consolidation, TP3 post
1st cycle of Ara-C)
RQ-PCR/cDNA NA 10−4–10−5
Mencia-Trinchant et al.,
2017 [59]/- 3/- NA
Sequential determination of
MRD levels ddPCR/cDNA
multiplex assay effective
in a range of diverse
common and rare NPM1
mutations (14)
10−4–10−5
Getta et al.,
2017 [60]/retrospective
104 (10 with NPM1
mutation)/58 (21–78)
58 BM at diagnosis,
83 BM before HSCT
for NGS
NA NGS, MFC/DNA 2 different mutations 10−4
Bill et al.,
2018 [61]/retrospective 51/62 (33–74) 51 (40 PB/11 BM)
samples collected directly
before HSCT ddPCR/cDNA A, D 10
−4
Jongen-Lavrencic et al.,
2018 [62]/retrospective
430 (168 with NPM1
mutation)/51 (18–66)
482 PB/BM samples at
diagnosis, 430 BM
samples after treatment
2 (at diagnosis and in CR) NGS, MFC/DNA NA 10−4
Zhou et al.,
2018 [63]/retrospective 59/57(21–79) 104 BM pre-HSCT and post-HSCT NGS, MFC/DNA - 10
−4
Zappasodi et al.,
2018 [64]/retrospective,
real-life study
201 (116 with NPM1
mutation)/58 NA
Availability of samples
during treatment and
follow-up was variable.
RQ-PCR/cDNA NA 10−4–10−5
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Table 1. Cont.
Reference/Type of
Study
Number of Patients/Median
Age (Years, Range)
Number of Samples
(PB/BM)
Number of Samples per
Patient (Median, Range)
Molecular
Method/Material NPM1 Mutation Type
Sensitivity of the
Assay
Delsing Malmberg et al.,
2018 [65]/retrospective 29/49 (18–66) 83 (6 PB/77 BM)
3 (at diagnosis, before and
after HSCT) NGS/DNA
all recurrent insertion
mutations in NPM1 exon
12 (mutation A in
25 cases)
10−4
Kapp-Schwoerer et al.,
2018 [66]/retrospective 611/18–60
6339 (2812 PB/
3527 BM)
NA (samples analyzed at
diagnosis, during treatment
and follow-up)
RQ-PCR/cDNA NA 10−5–10−6
Caprioli et al.,
2018 [67]/retrospective 27/57 (23–65) 27 BM 1 (pre alloHSCT) RQ-PCR/cDNA NA 10
−4
Patkar et al.,
2018 [68]/retrospective 83/NA NA NA NGS/DNA 12 different mutations 10
−5
Onecha et al.,
2018 [69]/retrospective
63 (57 with NPM1
mutation)/54 (42–66)
106 BM (51 after
induction, 55 post
consolidation CHT)
2 NGS/DNA A 10−5
Petrova et al.,
2018 [70]/retrospective
90 (22 positive for IDH1/2
mutations, 11 with NPM1
mutation)/61 (22–82)
149 BM
NA (90 at diagnosis, 22 after
induction, 37 during
follow-up)
RQ-PCR for NPM1
mutations/cDNA A NA
Prata et al.,
2018 [71]/retrospective
34 with newly diagnosed
NPM1-mutated AML/77
(55–85)
MRD assessment
available on BM
samples in 6 patients
NA RQ-PCR/NA A, B, D NA
Ottone et al.,
2018 [72]/retrospective
556 de novo AML (177 with
NPM1 mutation)/49 (16–89)
NA (BM samples at
diagnosis, during
follow-up, at relapse)
NA (NPM1-mutated
transcripts monitoring in
51 cases)
RQ-PCR/cDNA A 10−5
Gaksch et al.,
2018 [73]/retrospective
34 cytogenetically normal
AML (16 cases with NPM1
mutation)/47 (22–79)
34 BM or PB at
diagnosis, 27 BM
samples in remission
2 (at diagnosis and after at
least one
consolidation therapy)
NGS/DNA extracted
from BM slides
Multiplex analysis of
19 genes, including
NPM1 mutational
hotspots
10−2
MRD, minimal/measurable residual disease; AML, acute myeloid leukemia; PB, peripheral blood; BM, bone marrow; NA, not available; RQ-PCR, real-time quantitative polymerase chain
reaction; cDNA, complimentary DNA; HR, hematological relapse; CCR, continuous complete remission; NGS, next-generation sequencing; HSCT, hematopoietic stem cell transplantation;
CR, complete remission; TP, timepoint; ddPCR, digital droplet PCR; MFC, multiparametric flow cytometry; CHT, chemotherapy.
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The consensus document from the ELN MRD Working Party indicates that AML patients with
NPM1 mutations, such as patients with RUNX1-RUNX1T1, CBFb-MYH11 or PML-RARA fusion
transcripts, should have molecular MRD assessment at informative clinical timepoints. During the
active treatment phase, MRD assessment for these molecular lesions is recommended at minimum at
diagnosis, after 2 cycles of induction/consolidation chemotherapy, and at the end of treatment [74].
Furthermore, after the end of treatment, samples for MRD analyses should in general be collected
every 3 months for 24 months. Thereafter, monitoring beyond 2 years of follow-up should be based on
the relapse risk of the patient and decided individually [74]. Specifically regarding NPM1-mutated
AML, with or without other concomitant mutations, monitoring of NPM1 transcripts is recommended
in BM and PB, if possible. If NPM1-mutated MRD remains negative in PB but positive in BM after
the end of treatments, transcripts should be closely monitored every 4 weeks for at least 3 months,
in order to evaluate any MRD increase. Conversely, if a rising MRD is not confirmed or MRD becomes
undetectable, then MRD retesting may be regularly performed at 3-month intervals for at least the first
2 years after the end of treatment [74].
At first glance, the clinical management of NPM1-mutated AML patients according to these
recommendations could appear clearly defined. However, several controversial issues remain,
especially with regard to the most clinically significant timepoints and MRD thresholds to be
considered, but also with respect to the best source to be analyzed, namely BM or PB samples,
and correlation of MRD with other known prognostic indicators (Table 2) [8].
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Table 2. Clinical impact of MRD monitoring in NPM1-mutated AML patients.
Reference
Intensive
CHT/HSCT
(No. of Patients)
Significant MRD
Threshold Prognostic Timepoints
Correlation with
Other Molecular
Markers
Clonal Evolution
Median Time
since Molecular
to Morphologic
Relapse (Range)
Clinical Relevance
Gorello et al.,
2006 [30] Yes/NA
NA (3/5 cases with MRD
<1% long-term survivors) NA NA NA NA
- NPM1-mutated copies closely
correlated with clinical status
and predicted impending
hematologic relapse in 2 cases
Chou et al.,
2007 [31]
38 Yes/11
alloHSCT 0.1%
End of consolidation;
follow-up
FLT3-ITD
worsened RFS No
4.9 months
(1–12.3)
- Any rise of mutant signals
during follow-up increased
relapse risk
- MRD < 0.1% predicted longer
RFS and OS
- Failure to achieve 2 logs
reduction after consolidation
predicted shorter RFS and OS
Papadaki et al.,
2008 [32]
50 Yes/11
alloHSCT
NA (median log10
reduction of 2.48 post
induction correlated with
response to therapy)
NA NA
In 2/21 relapses
(9.5%) NPM1
mutation was lost.
NA
- In selected patients, it was
possible to correlate the
changes of the NPM1 mutation
A levels with the clinical course
of the disease
Barragan et al.,
2008 [33] 24 Yes/NA
NA (in 19 patients in CCR
a median 3% MRD after
induction was shown.
Median MRD level after
consolidation 0.3%
NA
Expression levels
of WT1 and NPM1
showed strong
positive
correlation.
No
MRD increase 1 to
5 months before
relapse in 4/6
cases
- MRD negativity or
maintenance of very low levels
of NPM1 mutation in patients
in continuous CR
- Increase in NPM1 transcripts
before or at the time of relapse
Bacher et al.,
2009 [34] -/13 alloHSCT NA
All 4 patients (29%) with
persistent MRD positive
after HSCT relapsed
Correlation with
molecular
chimerism.
No 24 days (12–38)
- After HSCT 10/14 cases (71%)
PCR-negative, of which 4
achieved stable CR.
- MRD increase preceded
morphologic relapse
Schnittger et al.,
2009 [35]
252 Yes/53
alloHSCT
0.01% during 1st line
treatment.0.1% after
HSCT and during 2nd
line treatment.
- early assessment
(days 18–60)
- days 60–121
- days 121–365
- longer than 1 year
after start
of treatment
FLT3-ITD
prognostic factor
affecting EFS
No 62 days (15–221)
- MRD for NPM1 mutation
assessed at 4 different time
intervals after start of therapy
(mainly after day 60) is an
independent and highly
predictive parameter for EFS.
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Table 2. Cont.
Reference
Intensive
CHT/HSCT
(No. of Patients)
Significant MRD
Threshold Prognostic Timepoints
Correlation with
Other Molecular
Markers
Clonal Evolution
Median Time
since Molecular
to Morphologic
Relapse (Range)
Clinical Relevance
Stahl et al.,
2010 [36] -/25 alloHSCT NA Post-HSCT follow-up
High rate of
congruent results
with chimerism
analysis
No NA
- Concordant results in BM and
PB in 60% of sample pairs.
- Cases with <0.01% MRD in BM
were negative in PB.
- Higher MRD levels in BM
(>0.2%) predicted PB positivity
Dvorakova et al.,
2010 [37]
25 Yes/4
alloHSCT
Reappearance of NPM1
mutation or one order
NCN increase in patients
with persistent positivity
at any timepoint.
NA NA No 97 days (12–141)
- Molecular relapse preceded
hematological relapse in 80% of
evaluable patients.
- Strong correlation between PB
and BM samples
Ommen et al.,
2010 [38] NA/NA
0.005% (threshold to
define molecular relapse) NA
More rapid MRD
growth in
FLT3-ITD+ cases
No
120 days without
FLT3-ITD, 65 days
in FLT3-ITD+ cases
- Mathematical model to
determine the frequency of
relapse detection
- Sampling every 4 and 6 months
suggested in FLT3-ITD+ and
negative cases, respectively
Kristensen et al.,
2011 [39] 20 Yes/NA NA
Reoccurrence of NPM1
mutation at any time
was associated with
relapse.
NPM1 mutation is
superior to WT1
expression levels
as MRD marker.
No (NPM1
mutation stability.
Karyotype
evolution in 56%
of relapses).
46 days (20–182)
- All relapses were associated
with high levels of
NPM1 mutation
- Detectable NPM1 mutation
following a CR period was
accompanied by morphologic
relapse in all cases
Kronke et al.,
2011 [40]
245 Yes/80
alloHSCT 2%
- -MRD negativity
after 2
induction cycles
- -After completion
of therapy
- -During follow-up
FLT3-ITD
significant factor
for inferior
survival.
In 5 patients
NPM1 mutation
was not detectable
at relapse (9% of
evaluable relapse
samples)
2.6 months
(0.4–23.6)
- Observation of higher
NPM1-mutated transcript
levels after double induction or
after completion of
consolidation therapy was a
significant factor for higher risk
of relapse and death.
- Serial post-treatment MRD
assessment allowed early
detection of relapse
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Table 2. Cont.
Reference
Intensive
CHT/HSCT
(No. of Patients)
Significant MRD
Threshold Prognostic Timepoints
Correlation with
Other Molecular
Markers
Clonal Evolution
Median Time
since Molecular
to Morphologic
Relapse (Range)
Clinical Relevance
Thol et al.,
2012 [41] 10 Yes/NA
NA
(mean allelic ratio at
diagnosis 0.37,
range 0.29–0.46)
NA NA
NPM1 mutation
not detectable in
1/4 patients at
relapse.
NA
- Parallel assessment of MRD by
NGS and RQ-PCR was
concordant in 95% of
analyzed samples
- NGS as a potentially highly
flexible and reliable tool to
assess MRD
Abdelhamid
et al., 2012 [42] 20 Yes/NA NA After induction therapy
Similar kinetics of
FLT3-ITD, NPM1
and WT1
expression for
predicted clinical
trend.
No NA for NPM1mutation
- The 3 MRD markers tested
showed comparable kinetics in
17/20 (85%) cases
Schiller et al.,
2012 [43]
54 (30 NPM1-
mutated) Yes/7
alloHSCT
NA
NA (samples collected
at diagnosis, during
treatment and
follow-up)
MRD for FLT3-ITD
as sensitive as
other MRD
parameters as
NPM1 mutations
or MLL-PTD
NA NA
- MRD negativity predicted
lasting remission independent
of alloHSCT or non-alloHSCT
- FLT3-ITD analyses equivalently
sensitive in PB samples
Shayegi et al.,
2013 [44]
155 Yes/40
alloHSCT
-MRD level >1% after
conventional CHT-MRD
level >10% after alloHSCT
After intensive CHT
and after HSCT
Prognostic role of
MRD remained
significant after
adjustment for
FLT3-ITD status
No
- 121 days
(70–172) for
MRD > 1%
- 66 days
(34–98) for
MRD > 10%
- Rising of MRD was associated
with increased risk of relapse.
- DFS and OS analyses revealed
significantly worse outcomes in
patients with rising MRD levels
Jeziskova et al.,
2013 [45]
8 Yes/4
alloHSCT NA NA
Concordance of
quantitative
detection of IDH2
and NPM1
mutations, except
for on case.
NA NA
- In 5/6 patients, the kinetics of
IDH2 quantification was nearly
identical to the kinetics of
NPM1 mutations
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Table 2. Cont.
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Intensive
CHT/HSCT
(No. of Patients)
Significant MRD
Threshold Prognostic Timepoints
Correlation with
Other Molecular
Markers
Clonal Evolution
Median Time
since Molecular
to Morphologic
Relapse (Range)
Clinical Relevance
Salipante et al.,
2014 [46] 6 Yes/NA NA NA NA
In 2 patients
genetically distinct
NPM1 tumor
subclones were
detected
NA
- As a proof of principle, NGS
documented MRD in all
samples deemed negative by
flow cytometry, without the
need for
mutation-specific probes
Hubmann et al.,
2014 [47]
158 Yes/30
alloHSCT
cut-off ratio 0.01 and 3-log
reduction After induction CHT
Prognostic role of
MRD regardless of
ELN risk
stratification.
NPM1 mutation
not detectable in 3
of 45 (6.7%)
patients at relapse
58 days (20–98)
- Assessment of MRD levels after
induction was significant to
identify patients in CR with
high risk of relapse. There was
also a trend for OS
Bacher et al.,
2014 [48] 99 Yes/NA 0.01%
- days 18–60
- days 61–120
- days 121–365
- >day 365
NA No NA
- NPM1 mutation levels by
digital and conventional
RQ-PCR significantly
correlated a diagnosis and
during follow-up
- digital PCR threshold of 0.01%
prognostically relevant.
Lambert et al.,
2014 [49] 77 Yes/NA 0.1% (in BM samples)
- after
induction CHT
- at the end
of treatment
After adjustment
for FLT3-ITD
status, the effect of
NPM1 MRD
appeared to be
similar.
No NA
- WT1 MRD associated with
increased hazard of relapse and
shorter OS from CR.
- Positive NPM1-mutated MRD
predicted higher risk of relapse,
but did not influence OS
- Achievement of negative NPM1
mutation MRD significantly
more frequent in GO arm
Debarri et al.,
2015 [50] 31 Yes/NA 0.1%
- post
induction CHT
- post first and
second
consolidation courses
Analysis of
correlation
between NPM1
mutations and
IDH1/2 or
DNMT3A
mutations
One patient with
IDH2 mutation
developed a
NPM1-negative
MDS
NA
- IDH1/2 mutational status by
NGS predicted relapse or
disease evolution in 100% cases
- DNMT3A mutations not
correlated with disease status
(a preleukemic clone persisted
in 40% of cases in CR)
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Pettersson et al.,
2016 [51] 15 Yes/5 HSCT 0.1% During follow-up NA
One of 8 relapsing
patients developed
a NPM1-negative
relapse
NA
- RQ-PCR of NPM1 A type
mutation was more sensitive
and reliable than MFC for
determination of MRD
Karas et al.,
2016 [52] -/60 alloHSCT 0.1%
pre-transplant (less than
1 week prior to start
conditioning regimen)
FLT3-ITD
positivity had no
adverse effect on
HSCT outcome in
patients with AML
with NPM1
mutation in CR
No
4 months (3–13)
from HSCT to
relapse, especially
in patients with
high preHSCT
MRD
- older age and pre-transplant
MRD had independent
prognostic impact on EFS
and OS
- 3-year relapse rate, EFS and OS
were 6%, 72%, 75% with
low-level MRD and 48%, 35%,
40% in patients with higher
MRD levels
Alizad
Ghandforoush
et al., 2016 [53]
11 Yes/6
alloHSCT <5 log reduction during follow-up NA No NA
- Relapse occurred in 6 (54.5%)
patients, whose NPM1
mutation levels showed less
than 5 log reduction
after treatment
Ivey et al.,
2016 [54]
346 + 91 Yes/82
alloHSCT 0.01%
after second CHT cycle
(PB samples)
Presence of
FLT3-ITD or
DNMT3A
mutations did not
provide additional
prognostic
information
NPM1 mutations
detectable in
69/70 (99%)
patients at relapse
133 days (BM), 87
days (PB)
- Persistence of NPM1 mutated
transcripts, observed in 15% of
patients after second CHT cycle,
associated with greater risk of
relapse after a 3-year follow-up
and lower survival rate
(24% vs. 75%)
- MRD as the only independent
prognostic factor for death
Kayser et al.,
2016 [55] -/67 alloHSCT 1% prior to alloHSCT
FLT3-ITD status
had no impact on
prognosis
No NA
- Significant difference in OS
after alloHSCT between
pre-transplant MRD-positive
and MRD-negative patients
(estimated 5-year OS rates
40% vs. 89%)
- Outcome of patients with
preHSCT MRD positivity as
poor as that of cases
transplanted with
refractory disease
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Malmberg et al.,
2017 [56] NA/NA 0.001% NA
CPS1, FAM193A,
ITGB7 NA NA
- For mutation load of NPM1,
good correlation between
results from deep sequencing
and RQ-PCR
- Targeted deep sequencing more
sensitive for MRD
quantification than MFC
Balsat et al.,
2017 [57]
152 Yes/44
alloHSCT
4-log reduction in PB
MRD
post-induction CHT
cycle
Abnormal
karyotype,
FLT3-ITD, PB
MRD associated
with higher
relapse incidence
and shorter OS.
No NA
- Patients without early MRD
reduction had higher incidence
of relapse and shorter OS
- In patients with non favorable
AML, HSCT improved
outcomes only in case of <4-log
reduction PB-MRD
Schieppati et al.,
2017 [58]
68 Yes/9
alloHSCT 0.5% TP1 (BM), TP3 (PB)
FLT3-ITD did not
impact on
relapse risk
No NA
- Molecular MRD monitoring of
crucial importance in detecting
relapse at an early stage
Mencia-Trinchant
et al., 2017 [59] 3 Yes/- NA NA NA No NA
- Novel ddPCR technique
composed of massively
multiplex pools of
insertion-specific primers that
selectively detected virtually all
NPM1 mutations in a manner
that was robust to clonal
heterogeneity and did not
require NPM1
sequence information
Getta et al.,
2017 [60] -/104 alloHSCT <5% VAF before HSCT NA No NA
- Mutations in DNMT3A, TET2,
JAK2 less likely to be cleared
than NPM1 (negative in 8/9
cases), IDH1/2, FLT3-ITD
- MRD detected concurrently
with MFC and NGS conferred
the highest relapse risk
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Bill et al.,
2018 [61] 51 Yes/51 HSCT 0.01% prior to HSCT
Adverse
prognostic role of
NPM1 mutation
MRD independent
of other known
prognostic
markers
NA
101 days after
HSCT (median
time to relapse for
all patient cohort)
- 17/51 (33.3%) patients were
MRD positive before HSCT
- The 2-year cumulative
incidence of relapse was 64.7%
vs. 6% translating into OS
38.8% vs. 71.7% in pre HSCT
MRD+ and
MRD-negative, respectively
Jongen-Lavrencic
et al., 2018 [62] 430 (168) Yes/ 2.5% allele frequency
samples obtained
during a defined period
of remission, between
21 days and 4 months
after start of second
treatment cycle
- NA NA
- mutations persisted in 51.4% of
patients during CR
- Persistent DTA mutations not
correlated with increased
relapse rate
- Persistent non-DTA mutations
conferred higher relapse rates
and lower survival rates
Zhou et al.,
2018 [63] -/59 alloHSCT 0.01%
pre-HSCT and post
HSCT (around day +28)
Peri-HSCT MRD
independent
prognostic factor
No NA
- Before HSCT MRD detected by
MFC was the most significant
risk factor for relapse
- NGS testing of NPM1-mutated
post-HSCT improved the risk
assessment of relapse
Zappasodi et al.,
2018 [64]
201 Yes/4
alloHSCT NA
MRD negativity at any
time, during or after the
end of 1st line treatment
NA No NA
- molecular CR obtained in
73.7% of NPM1-mutated cases
- molecular CR at the end of
treatment prognostic factor for
DFS and OS in
NPM1-mutated AML
Delsing
Malmberg et al.,
2018 [65]
-/29 alloHSCT 0.02% pre and post-HSCT
MRD was an
independent risk
factor associated
with clinical
outcome
No
4.5 months (3.5–11)
for MRD+; 7.7
months (7–32) for
MRD-cases
- Post-HSCT deep sequencing
MRD status was significantly
associated with clinical
outcome (3-year OS 20%
vs. 89%)
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Kapp-Schwoerer
et al., 2018 [66]
611 Yes/162
alloHSCT 2%
post two CHT cycles
(BM)
NPM1 MRD
negativity
associated with
lower relapse rate
and better OS
independent of
DNMT3A and
FLT3-ITD
mutations
No NA
- Outcome of patients who
became MRD negative or
remained positive but had 2017
ELN favorable risk profile was
superior after high-dose AraC
consolidation than
after alloHSCT
- MRD monitoring useful to
inform post-remission therapy
Caprioli et al.,
2018 [67] -/27 alloHSCT 0.01% pre-alloHSCT NA No NA
- molecular analysis had higher
sensitivity than MFC
- Low-level or negative MRD
associated with improved LFS
Patkar et al.,
2018 [68] 83 Yes/-
1-log cut-off between post
induction and post
consolidation
post induction and post
consolidation
NGS-MRD for
NPM1 mutations
as the most
independent
prognostic factor
No NA
- NGS was an useful test for
prediction of relapse
and survival
- NGS and MFC may be
complementary, with patients
MRD-negative by both
techniques having
excellent outcome
Onecha et al.,
2018 [69]
50 Yes/7
alloHSCT
0.1% post
induction/0.025% post
consolidation
post induction and post
consolidation
Higher risk of
death in subjects
with advanced age,
MRD+ status or
with FLT3-ITD
No NA
- MRD+ status post induction
and post consolidation
associated with lower OS and
shorter DFS and OS (33% vs
81%), respectively
- NGS improved the capacity to
predict AML outcome over
MFC or RQ-PCR
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Petrova et al.,
2018 [70] 22 Yes/NA NA NA
NPM1 mutation
MRD more
sensitive than
IDH1/2-based
MRD
NA NA
- ddPCR more sensitive than
NGS for IDH1/2 MRD detection
- In the absence of more sensitive
markers, IDH1/2 mutations can
be used as reliable markers for
MRD monitoring
Prata et al.,
2018 [71]
0/0
(34 patients
received upfront
therapy with
HMA)
NA
>3 log NPM1 MRD
reduction observed in
4/6 patients after
6 cycles, but three of
them relapsed within
<6 months of this
reduction.
No factors,
including type of
HMA, FLT3 and
IDH1/2 status,
were prognostic of
response or
survival
NA NA
- Overall response rate 45% (CR
in 23.5% of patients)
- Median OS 280 days
- No difference in OS between
cohorts with or without NPM1
mutations suggesting limited
therapeutic impact of HMA in
NPM1-mutated AML
Ottone et al.,
2018 [72] 177 Yes/NA NA NA
Evaluation of
correlation with
DNMT3A and
FLT3 mutations
NA NA
- NPM1-mutated transcripts
levels correlated with disease
course, as a reliable
MRD marker
- DNMT3AR882H levels did not
reflect AML status
Gaksch et al.,
2018 [73] 34 Yes/- VAF <0.5%
After at least one
consolidation cycle
In multivariate
analysis including
age, leukocyte
count and genetic
risk, residual
disease positivity
remained
statistically
significant as an
adverse factor
for RFS
NA NA
- Persistence of non-DNMT3A
mutations was significantly
associated with higher risk of
AML relapse and shorter RFS,
with a trend for shorter OS.
- Strong concordance between
NGS and ddPCR for
NPM1 mutations
MRD, minimal/measurable residual disease; AML, acute myeloid leukemia; CHT, chemotherapy; HSCT, hematopoietic stem cell transplantation; NA; not available; alloHSCT, allogeneic
HSCT; RFS, relapse-free survival; OS, overall survival; CR, complete remission; EFS, event-free survival; BM, bone marrow; PB, peripheral blood; NCN, normalized copy number;
NGS, next-generation sequencing; RQ-PCR, real-time quantitative polymerase chain reaction; DFS, disease-free survival; ELN, European Leukemia Net; GO, gemtuzumab ozogamycin;
MFC, multiparametric flow cytometry; TP, timepoint; ddPCR, digital droplet PCR; DTA (DNMT3A, TET2, ASXL1); VAF, variant allele frequency; LFS, leukemia-free survival, HMA,
hypomethylating agents (azacitidine, decitabine, guadecitabine).
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4. Prognostic MRD Thresholds and Relevant Timepoints for NPM1 Mutations
As above mentioned, several clinical trials have so far validated the clinical relevance of molecular
MRD monitoring in NPM1-mutated AML patients (Table 2), trying to identify prognostic MRD
thresholds and most relevant timepoints for collecting either BM or PB samples [30–73]. Schnittger et al.
retrospectively analyzed 1227 diagnostic and follow-up samples in 252 NPM1-mutated AML patients
by RQ-PCR assays [35]. A total of 47 relapses were predictable due to NPM1 mutation levels increase
of at least 1 log or in 15 cases because of a less than 3-log reduction in NPM1 mutation levels.
High prognostic value for MRD monitoring was documented at four different intervals after therapy
initiation (namely 18–60 days, 61–120 days, 121–365 days, >365 days), with levels of residual NPM1
transcripts as the most relevant factor affecting event-free survival (EFS) in multivariate analysis,
also in the subset of patients undergoing hematopoietic stem cell transplantation (HSCT). Moreover,
MRD thresholds of 0.01% and 0.1% NPM1-mutated/ABL1 obtained during first-line treatment and after
HSCT or second-line therapy, respectively, discriminated between prognostic subgroups, but without
influencing overall survival (OS) [35]. Another German-Austrian group evaluated MRD prognostic
role in 245 intensively treated adults with NPM1-mutated AML [40]. Achievement of RQ-PCR
negativity after double induction therapy identified patients with low 4-year cumulative incidence of
relapse (CIR), namely 6.5% compared with 53%, for subjects with persisting MRD positivity. This also
translated into significant differences in OS (90% versus 51%, respectively; p = 0.001). Furthermore,
according to Kronke et al., NPM1-mutated transcript levels were an independent prognostic factor also
when analyzed after completion of consolidation therapy (4-year OS 80% and 44% for MRD-negative
and MRD-positive patients, respectively) and during follow-up, when serial MRD monitoring allowed
early prediction of AML relapse in patients exceeding an arbitrary cut-off value of greater than 2%
NPM1-mutated/ABL1 [40]. Shayegi et al. subsequently investigated the prognostic impact of different
NPM1-mutated MRD cut-off values, among 155 AML patients treated within intensive treatment
protocols [44]. They found that MRD levels >1% after completion of conventional chemotherapy
were associated with increased relapse risk and significantly worse survival outcomes, whereas
for patients tested after having undergone HSCT, the best prognostic cut-off value for disease-free
survival (DFS) and OS was 10% NPM1-mutated/ABL1 [44]. Interestingly, Hubmann et al. monitored
molecular MRD during aplasia, after induction and consolidation chemotherapy, and during follow-up
in 158 patients with NPM1-mutated AML [47]. The assessment of MRD, with a cut-off ratio of 0.01 for
absolute NPM1-mutated ratios and a 3-log relative reduction, after induction therapy resulted the most
appropriate checkpoint in order to identify patients in CR at high risk of relapse. Indeed, the authors
observed 2-year CIR 77.8% and 26.4% for MRD-positive and MRD-negative after induction, respectively.
In this series, early molecular response thus seemed to be more prognostically relevant than persistent
MRD positivity after consolidation treatments [47]. Subsequently, Ivey et al. reported serial prospective
NPM1 mutation MRD monitoring in 346 AML patients enrolled in NCRI AML17 trial [54]. The major
finding of this large clinical study was that persistence of NPM1-mutated transcripts in PB samples
exceeding a value of 0.01% NPM1-mutated/ABL1 after the second chemotherapy cycle was associated
with a greater risk of relapse at a 3-year follow-up than was the absence of such mutated transcripts
(82% versus 30%, respectively; p < 0.001). Notably, MRD positivity after two treatment cycles was
observed in 15% of patients and also translated into lower OS rates in these subjects compared with
MRD-negative patients (24% versus 75%, respectively; p < 0.001). Additionally, the presence of MRD
at this testing timepoint was the only independent prognostic factor for death in multivariate analysis
and superseded other adverse baseline cytogenetic or molecular factors, such as FLT3-ITD or DNMT3A
mutations [54]. More recently, Balsat et al. reported on MRD evaluation in 152 NPM1-mutated AML
patients, showing that patients who did not achieve a 4-log reduction in NPM1-mutated transcripts in
PB samples after induction therapy (45% of study cohort) had a higher 3-year CIR (65.8% versus 20.5%)
and a shorter 3-year OS (40.8% versus 91.2%) compared with patients who obtained an adequate
MRD reduction [57]. Interestingly, the outcome of patients with a positive PB or BM MRD but with
>4-log reduction in PB MRD after induction treatment had a similar risk of relapse to subjects with
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both MRD negativity and >4-log reduction in PB MRD. Notably, in the subgroup of patients with
FLT3-ITD, only age, white blood cell (WBC) count and <4-log reduction in PB NPM1-mutated MRD
after induction, but not FLT3-ITD allelic ratio, were identified as prognostic factors. Among the
71 patients with non-favorable risk AML according to ELN risk stratification, DFS and OS were
significantly improved by allogeneic HSCT only in those with a <4-log reduction in PB MRD, whereas
this benefit was not documented in those with an MRD clearance >4-log, thereby suggesting the
potential use of early MRD investigation in PB as a predictive factor for HSCT indication [57].
Collectively, the results of the studies presented above confirmed that RQ-PCR is a reliable
molecular tool to assess MRD in most patients with NPM1-mutated AML [35,40,44,47,54,57]. The MRD
monitoring, by either a kinetic measure [32,35,47,53,57,68] or the obtainment of an absolute threshold of
NPM1-mutated transcripts [31,33,35,38,40,44,47–52,54–56,58,61,63,65–67,69], was overall predictive of
relapse and survival outcomes (Table 2). However, due to differences in patients’ cohorts and the lack
of standardization of NPM1-mutated RQ-PCR MRD assays and analytical methods, any comparison
between different studies remains extremely difficult, and evidence-based conclusions on the best MRD
thresholds and timepoints cannot be definitely drawn [8,44,75]. Interestingly, in the study by Balsat et
al., a positive MRD determination in BM and concurrent negativity in PB samples was found in 24.6%
of cases [57], in concordance with the 14.5% reported by Shayegi et al. in MRD samples collected at
different timepoints [44]. Absolute differences in NPM1-mutated RQ-PCR sensitivity generally favor
BM over PB on the order of 0.6–1.5 log10 [44,54,57,75], so that BM aspirate was initially considered
to be the best source to investigate MRD [75]. Also, in the series by Ivey et al., serial monitoring of
PB and BM paired samples confirmed that the BM analysis increased the rate of detection of MRD,
affording a median 1–log10 increment in sensitivity [54]. However, the presence of NPM1-mutated
transcripts, with a 0.01% absolute threshold to define positivity, in PB of patients after the second
chemotherapy cycle was highly discriminatory and was the only significant prognostic factor [54].
It has thus been hypothesized that MRD assessment in BM could overestimate the quality of response
due to the risk of BM samples dilution by PB, thereby justifying PB MRD monitoring at least at definite
timepoints [2,44,54,75], perhaps with 0.01% cut-off value to define MRD negativity, even though using
a >4-log reduction could also be considered reasonable [75]. Monitoring MRD in PB samples also
offers other advantages, such as decreased procedural morbidity and the possibility of more frequent
testing [8].
5. NPM1 Mutation Levels at AML Diagnosis
In most series, NPM1-mutated transcript levels at diagnosis did not correlate with the type of
NPM1 mutation or with other clinical characteristics, namely age, sex, WBC count, BM blast count,
lactate dehydrogenase level, ELN risk stratification or FLT3 gene mutational status [7,9,12,19,26].
On the contrary, Balsat et al. found higher median NPM1-mutated baseline levels in cases with WBC
count greater than 50 × 109/L or with FLT3-ITD positivity, whereas no significant correlation was
documented with age, karyotype or other concurrent gene mutations [29]. However, it should be
noted that pretreatment NPM1-mutated expression levels detected by RQ-PCR did not influence
CR rate after induction chemotherapy [19], CIR [19] and survival parameters, such as EFS and
OS [7,12,19,26]. Conversely, Patel et al. recently reported targeted sequencing data from 109 patients
with NPM1-mutated AML to retrospectively evaluate the potential significance of NPM1 variant
allele frequency (VAF) at diagnosis, comutations and clinical features on patient outcomes [76].
Interestingly, high NPM1 VAF (≥0.44) observed on NGS correlated with shortened median OS
(12.1 months versus not reached, p < 0.0001) as well as median EFS (7.5 versus 65.4 months, p < 0.0001).
High NPM1-mutated allele burden at diagnosis was an independent predictor of unfavorable clinical
outcomes, particularly in patients who received HSCT in first CR and in the subgroup of subjects
with concomitant DNMT3A mutations. Because of BM multilineage involvement of NPM1 mutations
not being restricted to cells with blast morphology [12,16,20], the VAF could in fact reveal the true
clonal disease burden. Higher NPM1 mutant allele burden may be less amenable to eradication by
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intensive chemotherapy, potentially resulting in a higher likelihood of MRD persistence. Alternatively,
high NPM1-mutated allele burden may indicate the presence of disease in different hematopoietic
cell populations, belonging to the NPM1-mutated leukemic clone regardless of blast morphology,
which could be intrinsically resistant to chemotherapy and could subsequently foster leukemia relapse,
resulting in adverse clinical outcomes [76].
6. Sequential MRD Monitoring and Molecular Prediction of Relapse
Several studies have investigated whether NPM1-mutated MRD monitoring during follow-up
of AML patients in CR after the end of intensive treatments could foresee hematologic
relapse [31,33–35,37–40,44,47,52,54,61,65]. Notably, post-treatment serial testing may portend
morphologic recurrence either when, in previously MRD-negative patients, NPM1-mutated transcripts
again become detectable or, alternatively, when rising MRD levels are observed in patients with
persistent low-level MRD positivity [75]. Ommen et al. documented that kinetics of molecular
relapse was markedly different among AML with NPM1 mutations or with rearrangements such
as PML-RARA, RUNX1-RUNX1T1 or CBFb-MYH11, and subsequently developed a mathematical
model to predict the time elapsing between molecular and hematologic relapse [38]. According to
this model, AML positive for CBFb-MYH11 displayed a slower clone regrowth than AML with other
molecular signatures, including NPM1 mutations [38,77]. In many patients who previously obtained
molecular CR, reoccurrence of NPM1-mutated transcripts may be detectable by molecular techniques
over 2–3 months before overt morphologic relapse occurred [1,31,33–35,37–40,44,47,52,54,61,65],
as summarized in Table 2, with significant differences observed between patients with concurrent
FLT3-ITD positivity or negativity (65 versus 120 days, respectively) [38]. Furthermore, median
time since molecular to hematologic relapse could also have a broad range, as documented by
Kronke et al. (median 2.6 months, range 0.4 to 23.6) [40], and may significantly vary according
to the NPM1-mutated/ABL1 cut-off value considered for MRD positivity, as shown in the study
Shayegi et al. [44]. Finally, Ivey et al. observed a longer time to overt relapse if molecular MRD was
first detected in BM rather than in PB samples (133 versus 87 days, respectively) [54]. These data
collectively suggest that serial molecular MRD assessment during follow-up may provide a timely
prediction of impending morphologic relapse in NPM1-mutated AML patients, potentially allowing
pre-emptive therapeutic approaches, preferably in the context of clinical trials [1,75,77].
7. MRD Levels and Allogeneic Hematopoietic Stem Cell Transplant in NPM1-Mutated AML
The use of alloHSCT in patients with NPM1-mutated AML is still controversial. In the
retrospective study by Rollig et al., a significant improvement in RFS was documented in the
donor group, indicating a beneficial effect of alloHSCT in NPM1-mutated AML patients in first
CR, also observed in the favorable subgroup without FLT3-ITD [78]. Even in the absence of a
significant difference in OS, most likely as a result of the fact that NPM1-mutated AML patients
experiencing relapse often achieved response to salvage treatments, alloHSCT could represent a
valuable consolidation option for NPM1-mutated AML patients in first CR if a sibling donor is
available, especially in young patients, with a relatively low risk of non-relapse mortality [78].
Unfortunately, prospective MRD monitoring was not performed within this trial [78]. Notably, several
subsequent studies investigated the prognostic significance of pre-transplant NPM1-mutated MRD
levels (Table 2) [52,55,57,60,61,63,65,67]. In detail, Karas et al., among 60 NPM1-mutated AML patients
undergoing alloHSCT, identified a significantly negative prognostic impact on EFS and OS, only for
age above 63 years and for pre-transplant MRD positivity, immediately before starting the conditioning
regimen, with cut-off 0.1% [52]. The estimated probabilities of 3-year relapse, EFS and OS were
6%, 72% and 75%, compared with 48%, 35% and 40% for patients with lower and higher levels
of MRD, respectively [52]. Kayser et al. reported on 67 NPM1-mutated AML patients, receiving
alloHSCT in either first (31 cases) or second (20 cases) CR or with refractory disease (16 cases) [55].
Overall, patients transplanted in CR had significantly longer OS as compared to patients with
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refractory disease. However, for patients undergoing alloHSCT in CR, there was a highly significant
difference in OS between pre-transplant MRD-negative and MRD-positive cases, with estimated
5-year OS rates of 89% versus 40%, respectively. Interestingly, these latter patients had an OS rate
comparable to that observed in patients receiving alloHSCT with refractory disease (38%). According
to Kayser et al., pre-transplant NPM1-mutated MRD positivity (>1%) was a significant predictor
of poor outcome after alloHSCT, independently of other variables, such as FLT3-ITD mutational
status, BM blast count at diagnosis and age [55]. More recently, Bill et al. applied highly sensitive
ddPCR to quantify pre-transplant NPM1-mutated MRD in 51 patients [61]. The 2-year CIR was
64.7% versus 6%, translating into OS rate 38.8% versus 71.7% in pre-transplant MRD-positive and
MRD-negative cases, respectively. Thus, pre-transplant MRD persistence independently predicted
adverse outcomes also in this cohort, including a large proportion of older patients (86.3% of
cases, with median age 62 years), mainly receiving non-myeloablative conditioning regimens [61].
Interestingly, the recommendation to perform alloHSCT only based on other known prognostic factors,
without considering pre-transplant NPM1-mutated MRD levels, is currently questionable [52,55,61].
According to Balsat et al., pre-transplant MRD assessment demonstrated that a survival benefit from
alloHSCT was not seen for patients with >4-log NPM1-mutated MRD clearance, whereas it was
maintained for those with insufficient MRD clearance, suggesting the relevant use of MRD evaluation
in transplant selection, to be further validated in clinical studies [57,75]. However, it is so far uncertain
whether patients with persistent MRD positivity could benefit from additional chemotherapy cycles
before alloHSCT or, alternatively, from intensification of conditioning regimen, whenever possible.
Prospective clinical trials are warranted to identify treatment options to improve the prognosis of
NPM1-mutated AML patients resulting MRD-positive prior to alloHSCT [61].
Furthermore, since the first observation in a small patient cohort by Bacher et al. [34],
post-transplant NPM1-mutated MRD monitoring has been shown to be predictive of relapse in several
large retrospective series [35,36,44,63,65]. Schnittger et al. reported a significant effect on survival of
NPM1 mutation levels, with relevant threshold 0.1%, for samples analyzed between days 61 and 120
and between 121 and 365 after alloHSCT [35]. Similarly, Shayegi et al. documented that an increasing
MRD burden exceeding the threshold of 10% NPM1-mutated/ABL1 on RQ-PCR assay was strongly
associated with an increased risk of relapse, therefore resulting in significantly worse outcomes in
terms of DFS and OS [44]. Most recently, Zhou et al. retrospectively investigated the application of
NGS to improve prediction of post-alloHSCT relapse in 59 adults with NPM1-mutated AML [63].
While pre-transplant MFC testing identified a subset of high-risk patients in whom additional therapy
before HSCT could potentially be useful; high-sensitivity NGS analysis of NPM1-mutated around
day 28 after alloHSCT predicted morphologic relapse in 15 of 18 cases (83%). Peri-transplant MRD
evaluation, improving the risk assessment for relapse, may identify high-risk patients who could
benefit from pre-emptive treatments after alloHSCT [63]. Moreover, Delsing Malmberg et al. reported
that MRD analysis using targeted deep sequencing 3 months after alloHSCT was a strong independent
predictor of both relapse risk and OS in adult NPM1-mutated AML patients [65]. Specifically, the 3-year
OS was 20% ± 17.9% versus 88.6% ± 7.8% (p < 0.001) for MRD-positive and MRD-negative patients,
respectively [65]. The above-presented data clearly suggest that NPM1-mutated AML patients
undergoing alloHSCT should be carefully monitored by MRD assays after transplant in order to early
detect imminent morphologic relapse [55,61]. However, the use of early pre-emptive strategies, namely
tapering of immunosuppression, donor lymphocyte infusions, administration of hypomethylating
agents or other targeted drugs, in patients with persisting or re-occurring NPM1-mutated MRD
positivity after alloHSCT, are not currently standardized [55,61,75,79]. Based upon the pivotal
RELAZA phase 2 study, which evaluated the role of 5-azacitidine in 20 either AML or myelodysplastic
syndrome (MDS) patients with MRD positivity after alloHSCT [80], Platzbecker et al. recently
reported the results of RELAZA2 trial, which investigated MRD monitoring in 205 patients with
either advanced MDS (27 cases) or AML (178 cases, including 31 with NPM1 mutations), in CR
after either conventional chemotherapy only (58 cases) or consecutive alloHSCT (147 cases) [81].
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In 53 patients who became MRD-positive at a median of 100 days after start of screening, pre-emptive
5-azacitidine was administered, resulting in overall response rates of 71% and 48% in patients with
and without antecedent alloHSCT, respectively. At a median follow-up of 13 months, OS rate
was 76%, suggesting that MRD-guided therapy with an hypomethylating agent may prevent or
substantially delay morphologic relapse in high risk MDS or AML patients [81]. Moreover, Sockel et al.
pre-emptively treated with 5-azacitidine 10 NPM1-mutated AML patients in first or second CR after
intensive chemotherapy or autologous or allogeneic HSCT (3 cases), who experienced either molecular
relapse or persistently detectable MRD positivity in sequential RQ-PCR analyses [82]. Molecular
response, with at least 1-log decrease in the MRD level compared with pretreatment value, was obtained
in 7 of the 10 patients. At a median follow-up of 10 months (range 2–12), a median of 5 cycles of
5-azacitidine were administered and the 7 patients remained in morphologic CR, suggesting a potential
efficacy of 5-azaciditine in controlling NPM1-mutated MRD [82]. Although post-transplant early
cellular or pharmacologic preemptive strategies to enhance graft-versus-leukemia effect or to eradicate
persistent MRD have preliminarily demonstrated improved outcomes, their definitive clinical efficacy
should be further investigated and determined in randomized clinical trials [79].
8. MRD Assessment in Elderly Patients with NPM1-Mutated AML
Incidence of AML is highest among older subjects, with a median age at disease onset of
67 years [83,84]. Despite the use of intensive chemotherapy in fit elderly patients, clinical outcomes
remain generally dismal, with lower CR rates (around 40–50%) and few long-term survivors compared
with younger patients [85,86]. Indeed, even when short-term benefits have been demonstrated,
very few patients older than 60 years actually become long-term survivors, with OS rates reported
to be <10% at 3 years and <5% at 5 years [85,86]. In addition to comorbidities, which commonly
hamper intensive treatment approaches, it should be noted that the genetic profile of AML in the
elderly is often unfavorable, with a high incidence of adverse-risk karyotypes and a lower frequency
of good-risk molecular features [83]. Accordingly, NPM1 mutations are found in only 20–25% of older
AML patients, and in 35–40% of those with normal karyotype [83,87]. The possibility of obtaining CR
remains relatively high (60–80%) in elderly NPM1-mutated AML patients [83,88]. However, while
NPM1-mutated AML in younger adults is generally associated with favorable clinical outcomes,
especially in the absence of FLT3-ITD, in older patients the risk of relapse is markedly higher (1-year
CIR 71% in patients aged >65 years) and survival significantly lower (2-year OS 19%) [88]. In this
disappointing clinical setting, NPM1-mutated MRD monitoring may potentially be useful for patients
who obtain morphologic CR in order to define the best personalized post-remissional treatment
approach and to early detect relapse [83]. However, although multiple series evaluating NPM1-mutated
MRD also enrolled some patients aged >60 years (Table 1) [31–37,39,42–45,47–56,58,60–63,65,67,69,71],
no study so far specifically focused on application and clinical significance of MRD monitoring
in elderly patients with NPM1-mutated AML. Since the most predictive timepoints and MRD
thresholds appear to be highly variable even between cohorts of younger adult patients, they cannot
be easily applied to elderly subjects with poor prognosis and future studies are needed to further
address these underexplored issues [83,89]. However, older AML patients frequently receive low to
moderate-intensity treatments, mainly with hypomethylating agents, able to prolong survival even
without the achievement of morphologic CR, thereby raising further controversies about the relevance
of MRD studies in this clinical context [71,83].
9. Clonal Evolution and Loss of NPM1 Mutation at AML Relapse
As expected for founder genetic lesions, NPM1 gene mutation is generally stable throughout the
course of the disease and has long been considered almost invariably present in patients experiencing
AML relapse [14,90,91]. Notably, it has been detected at relapse even many years after the initial
diagnosis, in patients experiencing more than one relapse and in relapses occurring in extramedullary
sites [14,92,93]. However, after the first observation by Papadaki et al. that two among 21 (9.5%)
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NPM1-mutated AML patients experiencing relapse, lost NPM1 mutation at leukemia recurrence [32],
many groups investigating NPM1-mutated molecular MRD provided further information on stability
of NPM1 mutation at relapse, as summarized in Table 2. While in several cohorts, clonal AML evolution
at disease recurrence was not observed [31,33–39,42,43,48,49,52,53,55,57–60,63–69], in the remaining
studies the frequencies of patients experiencing AML relapse with undetectable NPM1 mutations were
extremely variable, ranging from 1% in the prospective trial by Ivey et al. [54] to 25% documented
in smaller series [41,94]. Notably, cases with loss of NPM1 mutation at disease reoccurrence were
initially considered as secondary therapy-related myeloid neoplasms rather than true relapses from the
previously found NPM1-mutated leukemic clone [14,32,40]. Interestingly, to address the role of clonal
evolution in relapsed NPM1-mutated AML, Kronke et al. applied high-resolution SNP-array profiling
and performed comprehensive gene mutation screening in 53 paired BM/PB samples obtained at
diagnosis and relapse [95]. High stability between primary and relapse samples was observed for
mutations in DNMT3A (97%), IDH2 (92%) and NPM1 (91%) genes, whereas FLT3-ITD (75%) and
IDH1 (75%) were less stable. Interestingly, DNMT3A mutations were consistently documented in
primary and relapse samples from all the 5 cases with NPM1 mutation loss at relapse, suggesting
that DNMT3A mutation most likely preceded NPM1 mutation in the pathogenesis of the disease
and a common ancestral DNMT3A-mutated clone with NPM1 wild-type gave rise to both primary
and relapsed AML [95]. It should be noted that MRD monitoring based on RQ-PCR for NPM1
mutations may be hampered in the rare cases where relapse develops from an ancestral NPM1-negative
clone, probably arising from pre-existing non-malignant clonal hematopoiesis, therefore resulting in
false-negative MRD results [81,94,95]. Furthermore, a switch of the NPM1 mutation subtype from
D to A has been recently described in a patient with late NPM1-mutated AML relapse, 8 years after
the first diagnosis [96]. Clinical outcome of patients developing secondary AML with a switch of
the NPM1 mutation subtype may be misinterpreted by follow-up strategies only focusing on rising
MRD levels alone, which assume recurrence of the NPM1 mutation subtype previously documented
at initial diagnosis [96]. These rare circumstances demonstrated potential limitations of RQ-PCR in
MRD monitoring.
10. Newer Molecular Technologies to Assess MRD in NPM1-Mutated AML
A few studies have so far investigated the potential clinical application of newer molecular
methods, namely ddPCR [27,48,59,61] and NGS [41,46,56,60,62,63,65,68,69,73], to monitor MRD
in NPM1-mutated AML patients. As discussed above, at least 55 frameshift insertion NPM1
mutations have so far been recognized, and several other different gene lesions are theoretically
possible, rendering relative quantification of rare NPM1 mutations by conventional RQ-PCR highly
challenging [59]. Limitations of the application of RQ-PCR-based MRD assays are their dependence
on specific gene mutations, requiring individual reference standard curves based on target serial
dilutions, with commercial plasmid standards being widely available for only the three most common
NPM1 mutation types [59,77]. ddPCR, a high-throughput technology, instead generates absolute
quantification, can clonally amplify target nucleic acids, and does not require a reference standard
curve [10,77]. More specifically, in ddPCR assays the sample is separated in a large number of
partitions, and PCR reactions are compartmentalized to single oil droplets, which are then analyzed
for presence or absence of a target sequence based on fluorescence. Through the use of Poisson
statistics, the starting concentration of the target sequence is measured based on the number of
individual reactions in which it is found to be present [2,10,97]. According to the first few clinical
experiences in small NPM1-mutated AML patient series, ddPCR demonstrated excellent sensitivity and
agreement with RQ-PCR, also allowing for the detection of a variety of rare NPM1 mutation subtypes
(Tables 1 and 2) [48,59]. Notably, Mencia-Trinchant et al. created oligonucleotides with degenerate
sequence at known insertion sites and combined these massively multiplex pools of insertion-specific
primers into a single assay, which may selectively detect virtually all known and potential NPM1
mutations, but not wild-type NPM1 sequences [59]. Even if the precision of ddPCR assay, combined
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with its broad applicability also in patients ineligible for RQ-PCR MRD assessment, should be
recognized, it should also be noted that RQ-PCR actually still performs more than adequately for
MRD detection in most NPM1-mutated AML patients, is less expensive, and many clinical laboratories
already possess the equipment and technical expertise for this molecular analysis [98]. In addition,
primer mixes to detect multiple NPM1 mutation could also be used in RQ-PCR assays [35,37,54,99],
while Mencia-Trinchant et al. do not report whether their primer mix can potentially be utilized in
RQ-PCR assays [59]. However, the multiplexing of ddPCR could allow a future wider use of this
molecular tool in NPM1-mutated MRD monitoring, after further validation in prospective clinical
trials, at least in cases showing rarer mutations [97].
Furthermore, multi-gene NGS-based MRD monitoring has recently been applied to AML
patients, including those showing NPM1 mutations (Tables 1 and 2) [41,46,56,60,62,63,65,68,69,73].
NGS technologies, which allow parallel and repeated sequencing of millions of small DNA fragments
across many loci in order to evaluate either a few genes or an entire genome, may overcome some
of the limitations of single genes analysis based on RQ-PCR assays [10,75,77,100]. The ability of
NGS platforms to study large numbers of mutated genes could help to trace the evolution of
malignant clones [77]. However, the genetic clonal heterogeneity at AML diagnosis and during
the course of the disease could, conversely, complicate the MRD monitoring, because the predominant
leukemic clone at presentation may not be the same clone that determines clinical relapse and
mortality [77]. Moreover, intratumoral heterogeneity relies not only on the presence of different
somatic mutations in distinct leukemic subclones, but also on heterogeneity of transcriptional and
epigenetic states [101–103]. Unlike population-level approaches, single-cell RNA-sequencing platforms
enable transcriptomic analysis of an individual cell. Through the combination of high-throughput
sequencing and bioinformatic tools, single-cell RNA sequencing can detect more than 10,000 transcripts
in one cell to distinguish cell subsets and dynamic cellular changes, therefore revealing intratumoral
heterogeneity, with possible applications in identifying treatment-resistant leukemic cells and MRD
monitoring [101–103]. Another significant limitation of NGS technology initially was the intrinsic
error rate that limited its sensitivity for most single-nucleotide variants to 1–2% of all reads [1,104].
This notwithstanding, recent refinements of NGS technology, such as the introduction of random
barcodes that anneal to target sequence fragments prior to amplification or unique molecular indexes,
have eliminated the error rate of sequencing itself and markedly improved the assay sensitivity,
which is actually comparable or even superior to that of RQ-PCR or MFC [75,105]. Thol et al. first
conducted parallel assessment of MRD by NGS and RQ-PCR in a small series of NPM1-mutated AML
patients, observing concordance in 95% of the 38 analyzed samples [41]. As mentioned above, Zhou
et al. recently compared MRD testing by MFC and NGS before and after alloHSCT and showed that
NGS was approximately 10-fold more sensitive than MFC, also demonstrating the clinical utility of
high-sensitivity deep sequencing in risk assessment of relapse, especially after HSCT [63]. Moreover,
Onecha et al. optimized and validated a high-sensitivity NGS method to detect and quantify NPM1,
IDH1/2 and FLT3 mutated sequences, with survival analyses showing that MRD-positive status
tested by NGS was associated with higher risk of relapse and death, whereas MRD-negativity
at post-consolidation correlated with a longer DFS and OS [69]. Although NGS assay currently
shows a similar sensitivity to that of RQ-PCR, it does not require oligonucleotides that hybridize
specifically to a particular sequence, so all the nucleotides in the amplified region can be studied [69].
Consequently, the NGS test is capable of simultaneously detecting all NPM1 mutation types in a single
assay [41,46,56,65]. Therefore, the application of either NGS or multiplex ddPCR may be indicated for
follow-up quantification of rare NPM1 mutations subtypes, or alternatively in anecdotal cases of a
switch of the NPM1 mutation subtype during the course of the disease [69,96]. Despite these potential
advantages, NGS technology is still computationally demanding, time-consuming and expensive,
so that the ELN MRD Working Party suggests that NGS techniques for MRD measurement are actually
best reserved for clinical trials for further validation [74,77].
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11. Persistence of Pre-Leukemic Clones at AML Remission: What about NPM1 Mutations?
In the seminal analysis of comprehensive genomic data on samples collected from 50 patients
at AML presentation and remission after induction chemotherapy, Klco et al. documented persistent
leukemia-associated mutations in at least 5% of BM cells at remission in 48% of cases, which were
associated with increased relapse risk and reduced OS. Interestingly, contrary to other genes,
NPM1 mutations were cleared below the VAF 2.5% threshold at day +30 after chemotherapy in all the
18 NPM1-mutated AML analyzed cases [106]. Accordingly, Hirsch et al. reported, in a 69-AML-patient
cohort, that the detection of two or more events in >0.4% of cells by NGS assay after one treatment
course was strongly associated with lower survival in all cytogenetic profiles, especially in cases with
intermediate-risk cytogenetics [107]. Furthermore, Rothenberg-Thurley et al. characterized paired
pre-treatment and remission samples from 126 AML patients for mutations in 68 leukemia-associated
genes. Fifty cases (40%) retained, based on NGS analysis, at least 1 mutation during remission at a
VAF of ≥2%, with mutation persistence more frequently observed for DNMT3A (65%), SRSF2 (64%),
TET2 (55%) and ASXL1 (46%), whereas NPM1 mutation was rarely persisting (1/57 patients, 2%) [108].
Interestingly, among 46 patients with NPM1 mutation, there was a non-significant trend towards higher
molecular MRD levels by RQ-PCR in patients with compared to those without persisting pre-leukemic
lesions. A correlation was observed between persistence of pre-leukemic clones during first remission
and inferior OS and higher incidence of relapse, which was abrogated, in this series, by alloHSCT,
suggesting that mutation persistence may guide post-remission treatments [108]. More recently, further
information on the prognostic role of different persisting molecular lesions in AML patients at remission
has been provided [62,109]. Specifically, among 131 previously untreated AML patients, Morita et al.
observed frequent persistence of somatic mutation at CR in genes that are often pre-leukemic and
associated with clonal hematopoiesis of undetermined significance (CHIP), namely DNMT3A, TET2,
SRSF2, ASXL1 and TP53, whereas mutations in NPM1 gene, transcription factors or receptor tyrosine
kinase genes were often cleared [109]. Although the optimal VAF cut-off remains to be determined,
patients who achieved mutation clearance with a VAF <1% at day +30 after therapy, had significantly
better survival and lower risk of relapse in this series. These prognostic associations were more
pronounced when CHIP-related gene lesions were removed from the analysis [109]. In a larger cohort
of 482 AML patients, targeted NGS found persisting gene mutations in 51.4% of patients during CR,
with VAF ranging from 0.02% to 47%. The detection of persistent mutations in DNMT3A, TET2 and
ASXL1 genes (DTA mutations) was not correlated with an increased relapse rate. Only after exclusion
of DTA mutations from the analysis, the documentation of molecular MRD display significantly
higher relapse rates and lower survival rates, thereby confirming that persistent mutations in genes
associated with age-related CHIP did not have prognostic value in adult patients within a 4-year
time frame [62]. Overall, these studies provided information on the use of a genome-wide approach
to evaluate the impact of persistent multiple gene mutations on treatment outcomes [62,106–109].
The monitoring of specific single-gene MRD levels, including quantification of NPM1 transcripts
generally absent in pre-leukemic clones, could potentially be integrated with evaluation of persisting
pre-leukemic molecular lesions at remission. The combination of these two variables may ultimately
provide complimentary prognostic information and it could potentially be argued that monitoring both
leukemic and pre-leukemic clones after therapy could, in perspective, complement or even supersede
pre-treatment genetic factors for AML prognostic stratification [108].
12. Conclusions
Even though several published clinical studies (Tables 1 and 2) support the independent
prognostic significance of molecular MRD monitoring in NPM1-mutated AML patients, and the
Consensus Document from ELN MRD Working Party clearly indicates that patients showing NPM1
mutations should have molecular assessment of MRD, we have discussed that several controversies
have been raised, and further prospective clinical trials are warranted to standardize the optimal
material, timepoints, molecular tools and cut-offs for a meaningful application of MRD monitoring
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to inform treatment decisions [31,74,110]. Caution is still needed when using MRD results alone,
outside of a clinical trial, to make decisions with regard to treatment approaches with potentially high
morbidity and mortality, mainly alloHSCT, in otherwise genetically favorable-risk AML patients [8].
Interestingly, the application of pre-emptive, MRD-directed treatment strategies, potentially including
pharmacological agents targeting NPM1-mutated protein with induction of protein degradation or
drugs inhibiting NPM1 cytoplasmic translocation, such as selinexor, which acts through inhibition of
nuclear export and resulting in NPM1 protein nuclear relocalization, should be warranted and needs
to be prospectively investigated [111–113].
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